VetMedIsoxazolines for generalised demodicosis in dogs: fluralaner and sarolaner vs imidacloprid–moxidectin — LIKELY
In dogs with generalised demodicosis, do oral isoxazolines (fluralaner, sarolaner) vs imidacloprid–moxidectin clear mites and lesions?
Shelf #282 · gate-verified and approved by the developer
LIKELY: Oral isoxazolines clear Demodex mites in generalised demodicosis at least as completely as imidacloprid–moxidectin, and in these two small randomised laboratory studies more completely and sooner. In Fourie 2015 (16 dogs with naturally acquired generalised demodicosis, randomly allocated), a single oral fluralaner dose reduced mite counts in skin scrapings by 99.8% on day 28 and by 100% on days 56 and 84 (percentage reductions from pretreatment counts), vs 98.0%, 96.5% and 94.7% with three topical imidacloprid/moxidectin applications at 28-day intervals — statistically significantly fewer mites on the fluralaner dogs on days 56 and 84 (P ≤ 0.05). In Six 2016 (16 dogs with generalised demodicosis, randomly assigned), sarolaner on days 0, 30 and 60 reduced pretreatment mite counts by 97.1% at 14 days and 99.8% by 29 days, with no live mites detected thereafter, vs 84.4% and 95.6% reductions with weekly topical imidacloprid plus moxidectin, with no mites detected from day 74 on; all dogs in both groups showed marked improvement in clinical signs. Limits, stated plainly: two laboratory studies of 16 dogs each; randomisation is stated in both records but blinding is not established in either record (the build brief described the fluralaner comparison as blinded — the fetched record does not say so); the comparator regimens differ between the trials (monthly vs weekly imidacloprid/moxidectin); and the endpoint is mite counts over 12 weeks or less, not long-term relapse or cure. Anchor corrections recorded at the gate: the fluralaner vs imidacloprid/moxidectin trial is Fourie et al. 2015, not Six et al.; the sarolaner Demodex trial is Six et al. 2016 (Becskei second author) — Becskei et al. 2016 as first author is a sarcoptic mange trial, a different disease, and is not carded here. This shelf is demodicosis TREATMENT; isoxazolines for flea and tick PREVENTION are Shelf #7, a distinct question. Drafted Nov 10, 2026 (VetMed build, topic #282); all figures from abstracts fetched and verified at drafting.
Fourie 2015: single oral fluralaner dose — mite counts down 99.8% at day 28 and 100% at days 56 and 84, vs 98.0%/96.5%/94.7% on imidacloprid/moxidectin
Randomised laboratory study vs topical imidacloprid/moxidectin (publication type: Randomized Controlled Trial; abstract states random allocation; blinding not stated in the record)
Who: Dogs: sixteen dogs, all diagnosed with generalized demodectic mange (naturally acquired), in a laboratory study — randomly allocated to two equal groups: Bravecto (fluralaner) chewable tablets administered once orally at a minimum dose of 25 mg fluralaner/kg body weight, or Advocate (imidacloprid/moxidectin) applied topically on three occasions at 28-day intervals at a minimum dose of 10 mg imidacloprid/kg and 2.5 mg moxidectin/kg. Mites were counted in deep skin scrapings (~4 cm², from the same five sites on each dog) and demodectic lesions evaluated before treatment and at 28-day intervals over a 12 week study period.
Result: After single oral administration of Bravecto chewable tablets, mite numbers in skin scrapings were reduced by 99.8% on Day 28 and by 100% on Days 56 and 84 (percentage reductions from pretreatment counts). Mite numbers in the dogs treated topically on three occasions with Advocate were reduced by 98.0% on Day 28, by 96.5% on Day 56 and by 94.7% on Day 84. Statistically significantly (P ≤ 0.05) fewer mites were found on Days 56 and 84 on the Bravecto treated dogs compared to Advocate treated dogs. A marked decrease was observed in the occurrence of erythematous patches, crusts, casts and scales in the dogs treated with Bravecto and in the occurrence of erythematous patches in the dogs treated with Advocate. With the exception of one dog in each treated group, all dogs exhibited hair regrowth ≥90% at the end of the study in comparison with their hair-coat at study start. The record concludes a single oral administration of Bravecto is highly effective against generalized demodicosis, with no mites detectable at 56 and 84 days, while Advocate is also highly effective but most dogs still harboured mites at all assessment time points.
Watch out: Sixteen dogs (eight per group) in a laboratory study, and the record nowhere states blinding or masking of the mite counters — the build brief's description of this comparison as 'blinded' is not established by the fetched record and is not claimed on this card. The comparison is one fluralaner dose vs three monthly Advocate applications, so convenience is part of the contrast. Mite-count reductions are relative to each dog's pretreatment counts; the absolute anchor is 'no mites detectable' at days 56 and 84 on fluralaner.
Fourie JJ, Liebenberg JE, Horak IG, Taenzler J, Heckeroth AR, Frénais R. Efficacy of orally administered fluralaner (Bravecto™) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs. Parasit Vectors. 2015;8:187. PMID: 25881320. Registry ID: none in the record. MeSH: Animals · Dog Diseases · Dogs · Drug Combinations · Female · Imidazoles · Insecticides · Isoxazoles · Macrolides · Male · Mite Infestations · Neonicotinoids · Nitro Compounds
Six 2016: sarolaner (days 0, 30, 60) — mite counts down 97.1% at 14 days and 99.8% by 29 days, no live mites thereafter
Randomised laboratory study vs topical imidacloprid/moxidectin (abstract states random assignment; MeSH: Random Allocation; publication type indexed only as Journal Article; blinding not stated in the record)
Who: Dogs: in the first study in this record, 16 dogs with clinical signs of generalized demodicosis and positive for Demodex spp. mites, randomly assigned to oral sarolaner (Simparica) 2 mg/kg on Days 0, 30 and 60, or topical imidacloprid (10 mg/kg) plus moxidectin (2.5 mg/kg) solution every 7 days from Day 0 to Day 81.
Result: For sarolaner-treated dogs, pretreatment mite counts were reduced by 97.1% at 14 days and 99.8% by 29 days after the first dose, with no live mites detected thereafter (percentage reductions from pretreatment counts). Weekly imidacloprid plus moxidectin resulted in 84.4 and 95.6% reduction at these two time points, respectively, with no mites detected from Day 74 on. All dogs in both groups showed marked improvement in the clinical signs of demodicosis. There were no treatment related adverse events in either study in this record. The record concludes sarolaner at an oral dose of 2 mg/kg was highly effective in reducing the live mite counts associated with a natural infestation of Demodex spp.
Watch out: Sixteen dogs for the Demodex study, and blinding is not stated anywhere in the record. The comparator here was applied weekly (every 7 days to day 81) — a more intensive imidacloprid/moxidectin regimen than the monthly one in Fourie 2015 — so the two trials' comparator results are not interchangeable. The same paper's second study (induced Otodectes cynotis ear-mite infestations, placebo-controlled) is a different disease and is not evidence for this shelf; only the Demodex study is carded.
Six RH, Becskei C, Mazaleski MM, Fourie JJ, Mahabir SP, Myers MR, Slootmans N. Efficacy of sarolaner, a novel oral isoxazoline, against two common mite infestations in dogs: Demodex spp. and Otodectes cynotis. Vet Parasitol. 2016;222:62-6. PMID: 26971196. Registry ID: none in the record. MeSH: Animals · Dog Diseases · Dogs · Female · Insecticides · Isoxazoles · Male · Mite Infestations · Mites · Random Allocation · Treatment Outcome
Synthesis: two small randomised trials agree — isoxazolines reach zero detectable mites sooner; relapse beyond 12 weeks is untested here
Synthesis
Who: Synthesis of the cards above: Fourie 2015 (randomised laboratory study, 16 dogs, single-dose fluralaner vs three monthly imidacloprid/moxidectin applications) and Six 2016 (randomised laboratory study, 16 dogs, three monthly sarolaner doses vs weekly imidacloprid/moxidectin).
Result: Both isoxazolines drove mite counts to undetectable within about a month of the first dose (fluralaner: 100% reduction at days 56 and 84 after one dose; sarolaner: 99.8% by day 29, no live mites thereafter), while imidacloprid/moxidectin also worked but more slowly — most Advocate dogs still harboured mites at every time point in Fourie 2015, and the weekly regimen in Six 2016 reached zero only from day 74. Clinical signs improved markedly in both groups in Six 2016, and hair regrowth was ≥90% in all but one dog per group in Fourie 2015. For a clinician the supported claim is mite clearance and lesion improvement over 12 weeks against an active comparator — not prevention (Shelf #7), not sarcoptic mange, and not freedom from relapse after the study window.
Watch out: Combined, the demodicosis evidence carded here is 32 dogs in two manufacturer-programme laboratory studies, with randomisation stated but blinding not established in either record — that is why this shelf carries LIKELY rather than PROBABLE despite the near-total mite reductions. Field effectiveness in client-owned dogs with the comorbidities and compliance problems of real practice is a further step the carded trials do not take.
Synthesis of Fourie JJ et al. PMID: 25881320; Six RH et al. PMID: 26971196. Registry IDs as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.